Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Dance Biopharm Inc., a San Francisco-based biotechnology company focused on the development of inhaled insulin products to treat diabetes, this week announced that it had entered into a joint venture with Hong Kong-based Harmony Asset for the development of Adagio, a novel inhaled insulin product, in China and other Asian countries (excluding Japan).
According to a press announcement, under the terms of the joint venture Harmony will cover the majority of the development expenses in most of the specified regions and will receive ownership in those territories commensurate with the level of expenses paid. The joint venture will enable Dance Biopharm to significantly expedite its regulatory, manufacturing, and commercial partnering efforts in China.
http://www.biotecheast.com/modules.php?op=modload&name=News&file=article&sid=2623&topic=2
Hadn't heard of this one before, Mannkind seems to be the big player. This is a liquid rather than a powder. Still not keen!
According to a press announcement, under the terms of the joint venture Harmony will cover the majority of the development expenses in most of the specified regions and will receive ownership in those territories commensurate with the level of expenses paid. The joint venture will enable Dance Biopharm to significantly expedite its regulatory, manufacturing, and commercial partnering efforts in China.
http://www.biotecheast.com/modules.php?op=modload&name=News&file=article&sid=2623&topic=2
Hadn't heard of this one before, Mannkind seems to be the big player. This is a liquid rather than a powder. Still not keen!